Wedbush initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $8 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- CAMP4 Therapeutics Unveils Promising Data at ASGCT 2025
- Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
- CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)
- CAMP4 Therapeutics Advances RNA-Based Therapeutics